The role of DMARDs in systemic sclerosis therapy

Rheumatology

Volumn 45, Issue SUPPL. 3, 2006, Pages

  Blank, Norbert ^a   Max, R ^a   Lorenz, H M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG FIBROSIS; MEDICAL EXPERT; METHODOLOGY; OUTCOME ASSESSMENT; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SAMPLE SIZE; SCORING SYSTEM; SKIN DISEASE; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; HUMANS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 33748987038     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel289     Document Type: Article

References (15)

1. Lin AT, Clements PJ, Furst DE. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin North Am 2003;29:409-26.
2. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004;23:306-9.
3. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24-week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
4. Pope JE, Bellamy N, Seibold JR et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
5. Clements PJ, Lachenbruch PA, Sterz M et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993;36:75-83.
6. Morton SJ, Powell RJ. Cyclosporin and tacrolimus: Their use in a routine clinical setting for scleroderma. Rheumatology 2000;39:865-9.
7. Filaci G, Cutolo M, Basso M et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology 2001;40:1431-2.
8. Airo P, Danieli E, Parrinello G et al. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004;22:573-8.
9. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002;29:298-304.
10. Denton CP, Merkel PA, Furst DE et al. Anti-TGFβ1 Therapy for Diffuse Cutaneous Systemic Sclerosis: A multicenter, randomized, placebo-controlled Phase I/II Trial of CAT-192. Arthritis Rheum 2004;50(Suppl):S691-2.
11. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001;40:84-8.
12. Rook AH, Freundlich B, Jegasothy BV et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 1992;128:337-46.
13. Enomoto DN, Mekkes JR, Bossuyt PM et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999;41:915-22.
14. Grassegger A, Schuler G, Hessenberger G et al. Interferon-gamma in the treatment of systemic sclerosis: A randomized controlled multicentre trial. Br J Dermatol 1998;139:639-48.
15. van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: Hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005;64:1515.